[go: up one dir, main page]

MX2010002970A - Composiciones farmaceuticas liofilizadas. - Google Patents

Composiciones farmaceuticas liofilizadas.

Info

Publication number
MX2010002970A
MX2010002970A MX2010002970A MX2010002970A MX2010002970A MX 2010002970 A MX2010002970 A MX 2010002970A MX 2010002970 A MX2010002970 A MX 2010002970A MX 2010002970 A MX2010002970 A MX 2010002970A MX 2010002970 A MX2010002970 A MX 2010002970A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
administered
lyophilized pharmaceutical
orally
buffer
Prior art date
Application number
MX2010002970A
Other languages
English (en)
Inventor
Joseph Lawrence Zielinski
Thitiwan Buranachokpaisan
Wei-Qin Tong
Wenlei Jiang
Jiahao Zhu
Hans-Peter Zobel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40005335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010002970(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2010002970A publication Critical patent/MX2010002970A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composiciones farmac?uticas que incluyen un compuesto terap?utico pobremente soluble en agua, un solvente acuoso, un quelante/antioxidante, un regulador del pH o un componente regulador del pH, y un agente de volumen. Las composiciones farmac?uticas pueden ser oralmente ingeridas o se pueden administrar parenteralmente. Las composiciones farmac?uticas se pueden adem?s liofilizar para formar una torta farmac?uticamente aceptable que se pueda administrar oralmente, por ejemplo como una forma de dosificaci?n oral s?lida; o que se pueda reconstituir y administrar parenteralmente, por ejemplo como un solo bolo intravenoso o una infusi?n intravenosa, o se puede administrar oralmente, por ejemplo como una soluci?n para beber.
MX2010002970A 2007-09-20 2008-09-18 Composiciones farmaceuticas liofilizadas. MX2010002970A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97383007P 2007-09-20 2007-09-20
PCT/US2008/076752 WO2009039226A1 (en) 2007-09-20 2008-09-18 Lyophilized pharmaceutical compositions

Publications (1)

Publication Number Publication Date
MX2010002970A true MX2010002970A (es) 2010-04-01

Family

ID=40005335

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002970A MX2010002970A (es) 2007-09-20 2008-09-18 Composiciones farmaceuticas liofilizadas.

Country Status (20)

Country Link
US (1) US20100331387A1 (es)
EP (1) EP2205222A1 (es)
JP (1) JP2010540445A (es)
KR (1) KR20100059887A (es)
CN (1) CN101801345A (es)
AR (1) AR068822A1 (es)
AU (1) AU2008302273A1 (es)
BR (1) BRPI0817118A2 (es)
CA (1) CA2696914A1 (es)
CL (1) CL2008002786A1 (es)
CO (1) CO6270207A2 (es)
EC (1) ECSP10010039A (es)
GT (1) GT201000062A (es)
MA (1) MA31744B1 (es)
MX (1) MX2010002970A (es)
PE (1) PE20090706A1 (es)
RU (1) RU2010115262A (es)
TN (1) TN2010000097A1 (es)
TW (1) TW200930416A (es)
WO (1) WO2009039226A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017242544B2 (en) * 2016-03-31 2022-11-24 Midatech Ltd. Cyclodextrin-panobinostat adduct

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US7250514B1 (en) * 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
KR101139557B1 (ko) * 2003-07-23 2012-04-30 바이엘 파마슈티칼스 코포레이션 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아
JP2007501775A (ja) * 2003-08-07 2007-02-01 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤
PE20060664A1 (es) * 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
US20060128660A1 (en) * 2004-12-10 2006-06-15 Wisconsin Alumni Research Foundation FK228 analogs and methods of making and using the same
US7604939B2 (en) * 2005-03-01 2009-10-20 The Regents Of The University Of Michigan Methods of identifying active BRM expression-promoting HDAC inhibitors
AU2008204928B2 (en) * 2007-01-10 2011-03-31 Novartis Ag Formulations of deacetylase inhibitors
EP2120900A2 (en) * 2007-02-15 2009-11-25 Novartis AG Combination of lbh589 with other therapeutic agents for treating cancer

Also Published As

Publication number Publication date
ECSP10010039A (es) 2010-04-30
GT201000062A (es) 2012-03-30
CA2696914A1 (en) 2009-03-26
RU2010115262A (ru) 2011-10-27
PE20090706A1 (es) 2009-07-15
AR068822A1 (es) 2009-12-09
TW200930416A (en) 2009-07-16
TN2010000097A1 (en) 2011-09-26
CO6270207A2 (es) 2011-04-20
US20100331387A1 (en) 2010-12-30
WO2009039226A1 (en) 2009-03-26
CN101801345A (zh) 2010-08-11
JP2010540445A (ja) 2010-12-24
AU2008302273A1 (en) 2009-03-26
KR20100059887A (ko) 2010-06-04
CL2008002786A1 (es) 2009-05-15
MA31744B1 (fr) 2010-10-01
BRPI0817118A2 (pt) 2019-09-24
EP2205222A1 (en) 2010-07-14

Similar Documents

Publication Publication Date Title
WO2010039762A3 (en) Pharmaceutical compositions comprising boronic acid compounds
WO2007123995A3 (en) Camptothecin-analog with a novel, “flipped” lactone-stable, e-ring and methods for making and using same
MX343358B (es) Tabletas de acetato de ulipristal.
EP3895699A3 (en) Pharmaceutical compositions comprising iron oxy-hydroxide
WO2009032034A3 (en) Stabilized picoplatin dosage form
NZ588913A (en) Liver cancer drug
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
WO2007095091A3 (en) Oral delivery of therapeutic agents using tight junction agonists
WO2011159100A3 (ko) 항암 활성을 나타내는 약제학적 조성물
WO2007116102A3 (en) Therapeutic composition and use
UA122762C2 (uk) Пероральна композиція 9-[(2,2-диметилпропіламіно)-метил]-міноцикліну або його солі, тверда пресована дозована форма, композиція для ін'єкцій, застосування та спосіб приготування фармацевтичної композиції
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
MY143549A (en) Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases
WO2011083402A3 (en) Immediate release compositions of acid labile drugs
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
CA2688047A1 (en) Composition of biocompatible microparticles of alginic acid for the controlled release of active ingredients by intravenous administration
WO2007120838A3 (en) Rapidly disintegrating solid oral dosage form of liquid dispersions
TN2010000097A1 (en) Lyophilized pharmaceutical compositions
MX2012001107A (es) Derivado de amida.
WO2010029093A3 (en) Compositions for percutaneous administration
WO2012058276A3 (en) Methods and materials for reducing mutiple risk factors associated with the metabolic syndrom
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
WO2008009589A3 (en) Kit of parts comprising an acid labile and an acid resistant pharmaceutically active ingredient

Legal Events

Date Code Title Description
FA Abandonment or withdrawal